GGrantIndex
← Leaderboards

Michael R. Bristow

University Of Colorado Denver

$7,111,960
Attributed
$7,111,960
Total exposure
12
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $699.9K · FY200508
$1M$750K$500K$250K$0
'05
'06
'07
'08

Funding mix

By agency

NIH$7,111,960 · 12

By mechanism

R01$5,914,298 · 3
M01$964,673 · 8
T32$232,989 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectClinical ResearchGene ExpressionBeta Antiadrenergic AgentHeart FailureHuman Therapy EvaluationPolymerase Chain ReactionRenin Angiotensin SystemHeart CatheterizationCongestive Heart FailureHeart Disorder ChemotherapyHeart FunctionMyosinsEchocardiographyDrug Administration Rate /DurationIdiopathic Dilated CardiomyopathyBeta Adrenergic ReceptorHeart Imaging /Visualization /ScanningAdrenergic ReceptorMagnetic Resonance ImagingLongitudinal Human StudyMolecular PathologyCardiovascular Disorder ChemotherapyHeart Ventricle

Grant awards (34)

BETA-BLOCKER EFFECT ON REMODELING AND GENE EXPRESSION$1,187
M01 · FY2008 · RR · contact PI
Genetic-Adrenergic Interactions in Myocardial Failure$660,384
R01 · FY2007 · HL · contact PI
BETA-BLOCKER EFFECT ON REMODELING AND GENE EXPRESSION$10,099
M01 · FY2007 · RR · contact PI
Genetic-Adrenergic Interactions in Myocardial Failure$673,014
R01 · FY2006 · HL · contact PI
BETA-BLOCKER EFFECT ON REMODELING AND GENE EXPRESSION$26,921
M01 · FY2006 · RR · contact PI
Genetic-Adrenergic Interactions in Myocardial Failure$673,734
R01 · FY2005 · HL
BETA-BLOCKER EFFECT ON REMODELING AND GENE EXPRESSION$20,588
M01 · FY2005 · RR
Genetic-Adrenergic Interactions in Myocardial Failure$588,259
R01 · FY2004 · HL
Genetic-Adrenergic Interactions in Myocardial Failure$128,312
R01 · FY2004 · HL
Beta-Blocker Effect on Remodeling and Gene Expression$14,042
M01 · FY2004 · RR
ALTERED GENE EXPRESSION IN THE FAILING HUMAN HEART$447,428
R01 · FY2003 · HL
Dynamic Expression Profiling in the Intact Human Heart$153,000
R01 · FY2003 · HL
ALTERED GENE EXPRESSION IN THE FAILING HUMAN HEART$445,839
R01 · FY2002 · HL
CONTRACTILE PROTEIN EXPRESSION IN FAILING HUMAN HEART$377,500
R01 · FY2002 · HL
BETA ADRENERGIC BLOCKADE IN PATIENTS WITH CONGESTIVE HEART FAILURE$190,747
M01 · FY2002 · RR
EFFECTS OF CHRONIC TRTMNT WI BUCINDOLOL HCL OR METOPROLOL TARTRATE$190,747
M01 · FY2002 · RR
Dynamic Expression Profiling in the Intact Human Heart$151,000
R01 · FY2002 · HL
ALTERED GENE EXPRESSION IN THE FAILING HUMAN HEART$437,103
R01 · FY2001 · HL
CONTRACTILE PROTEIN EXPRESSION IN FAILING HUMAN HEART$377,500
R01 · FY2001 · HL
EFFECTS OF CHRONIC TRTMNT WI BUCINDOLOL HCL OR METOPROLOL TARTRATE$190,747
M01 · FY2001 · RR
BETA ADRENERGIC BLOCKADE IN PATIENTS WITH CONGESTIVE HEART FAILURE$190,747
M01 · FY2001 · RR
BETA ADRENERGIC BLOCKADE IN PATIENTS WITH CONGESTIVE HEART FAILURE$0
M01 · FY2001 · RR
EFFECTS OF CHRONIC TRTMNT WI BUCINDOLOL HCL OR METOPROLOL TARTRATE$0
M01 · FY2001 · RR
ALTERED GENE EXPRESSION IN THE FAILING HUMAN HEART$423,725
R01 · FY2000 · HL
CONTRACTILE PROTEIN EXPRESSION IN FAILING HUMAN HEART$377,500
R01 · FY2000 · HL
POSTGRADUATE TRAINING IN CARDIOVASCULAR RESEARCH$232,989
T32 · FY2000 · HL
EFFECTS OF CHRONIC TRTMNT WI BUCINDOLOL HCL OR METOPROLOL TARTRATE$32,212
M01 · FY2000 · RR
PARALLEL, DOSE RESP STUDY--SUSTND RELEASED MOXONIDINE IN CHF PATIENTS$32,212
M01 · FY2000 · RR
EFFICACY OF IV MILRINONE IN PATIENTS WITH CONGESTIVE HEART FAILURE$32,212
M01 · FY2000 · RR
BETA ADRENERGIC BLOCKADE IN PATIENTS WITH CONGESTIVE HEART FAILURE$32,212
M01 · FY2000 · RR
BETA ADRENERGIC BLOCKADE IN PATIENTS WITH CONGESTIVE HEART FAILURE$0
M01 · FY2000 · RR
PARALLEL, DOSE RESP STUDY--SUSTND RELEASED MOXONIDINE IN CHF PATIENTS$0
M01 · FY2000 · RR
EFFECTS OF CHRONIC TRTMNT WI BUCINDOLOL HCL OR METOPROLOL TARTRATE$0
M01 · FY2000 · RR
EFFICACY OF IV MILRINONE IN PATIENTS WITH CONGESTIVE HEART FAILURE$0
M01 · FY2000 · RR